Jun 24, 2026
FTC concerns over Amazon’s ad pricing practices add fresh pressure to a stock already sliding. Investors now face the risk of a potentially costly legal fight just as the shares are losing momentum.
Jun 23, 2026
As AI data centers reshape the power-hungry digital infrastructure market, Hut 8, TeraWulf, and Core Scientific are transforming former Bitcoin mining sites into high-value lease businesses. But while the rally is real, the upside may be strongest where cash flow is already coming in.
Jun 22, 2026
Beyond pharma, three overlooked companies could ride the explosive GLP-1 boom. Here’s how telehealth, discount retail, and glucose monitoring may benefit from the trend.
Jun 21, 2026
Aehr’s latest order adds fuel to an already huge 2026 rally, but the stock’s valuation now looks stretched. Investors may be waiting for sales and earnings to catch up.
Jun 20, 2026
Trupanion’s strong retention and record margins suggest its pet insurance model is working, but investors still want proof that growth can become lasting profit. The next few quarters may determine whether loyalty finally pays off.
Jun 19, 2026
Lower oil prices could lift airlines, logistics, and energy majors. Here’s why Delta, FedEx, and Chevron may be poised to benefit if supply fears ease.
Jun 18, 2026
With SpaceX now public, the idea of a Tesla merger is shifting from speculation to something Wall Street can actually price in. Dan Ives says the odds look high—and Elon Musk’s growing web of deals suggests the pieces may already be falling into place.
Jun 17, 2026
D-Wave faces rising pressure from both a nimble quantum cybersecurity upstart and a heavyweight chip giant with deep pockets. The article examines whether the pure-play leader can keep its edge as the competition heats up.
Jun 16, 2026
SpaceX’s blockbuster debut isn’t just lifting its own stock—it’s reshaping the entire orbital economy. With a tight float, heavy institutional demand, and looming index flows, volatility may be just getting started.
Jun 15, 2026
Robinhood’s new underwriter approval could expand its IPO role and deepen its appeal to retail investors. But the bigger story is how this move may strengthen its core business and long-term growth strategy.
Jun 14, 2026
These three big winners still look strong on the surface, but weakening charts and bearish momentum signals suggest the rally may be running out of steam. Here’s why Fortinet, Amprius, and AppLovin could be nearing a tactical exit point.
Jun 13, 2026
GSK’s $10.6 billion Nuvalent buyout highlights how Big Pharma is racing to plug looming patent-cliff revenue gaps. The all-cash deal could reset biotech valuations and spark more defensive deals across oncology.
